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Edited by Veli-Pekka LehtoAbstract It is known that chemokine-like factor superfamily 8
(CKLFSF8), a member of the CKLF superfamily, has four puta-
tive transmembrane regions and a MARVEL domain. Its struc-
ture is similar to TM4SF11 (plasmolipin) and widely distributed
in normal tissue. However, its function is not yet known. We
show here that CKLFSF8 is associated with the epidermal
growth factor receptor (EGFR) and that ectopic expression of
CKLFSF8 in several cell lines suppresses EGF-induced cell pro-
liferation, whereas knockdown of CKLFSF8 by siRNA promotes
cell proliferation. In cells overexpressing CKLFSF8, the initial
activation of EGFR was not aﬀected, but subsequent desensitiza-
tion of EGF-induced signaling occurred rapidly. This attenuation
was correlated with an increased rate of receptor endocytosis. In
contrast, knockdown of CKLFSF8 by siCKLFSF8 delayed
EGFR endocytosis. These results identify CKLFSF8 as a novel
regulator of EGF-induced signaling and indicate that the associ-
ation of EGFR with four transmembrane proteins is critical for
EGFR desensitization.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The chemokine-like factor superfamily (CKLFSF) is a novel
family of proteins consisting of at least nine members, CKLF
and CKLFSF1-8. CKLF was ﬁrst isolated from PHA-stimu-
lated U937 cells [1], whereas CKLFSF1-8 were subsequently
cloned by in silico gene identiﬁcation based on sequence simi-
larity [2]. CKLF and CKLFSF1-4 form a gene cluster on chro-
mosome 16q22.1, CKLFSF5 itself maps on chromosome
14q11.2 and CKLFSF6-8 form a gene cluster on chromosome
3p23. CKLF has conserved areas with chemokines such as
CCL22/ macrophage-derived chemokine (MDC), CX3C
chemokine ligand 1 (CX3CL1)/fractalkine and CCL17/ thy-
mus and activation-regulated chemokine (TARC), whereasAbbreviations: EGFR, epidermal growth factor receptor; CKLF,
chemokine-like factor; CCL, CC chemokine ligand; TM4SF, trans-
membrane 4 super family; MAL, myelin and lymphocyte protein;
MARVEL, MAL-related proteins for vesicle traﬃcking and mem-
brane link domain
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doi:10.1016/j.febslet.2005.10.021CKLFSF8 is structurally more similar to TM4SF11 (plasmoli-
pin), a member of the myelin and lymphocyte protein (MAL)
family, and shares 44% amino acid identity with TM4SF11. It
seems that CKLFs link the CKLFSF family with chemokines
and CKLFSF8 links the CKLFSF family with transmembrane
4 super family (TM4SF) families. The characteristics of
CKLFSF2-7 are intermediate between CKLFSF1 and
CKLFSF8. CKLFSF8 is the full-length cDNA product encod-
ing 173 amino acids. Although CKLFSF8 has four putative
transmembrane regions, it is not a typical tetraspanin, as there
is an absence of a Cys-Cys-Gly sequence (the CCG motif)
within the large extracellular loop of the protein [3]. CKLFSF8
has a predicted MAL-related proteins for vesicle traﬃcking
and membrane link domain (MARVEL) domain between ami-
no acids 36–168, which suggests that CKLFSF8 might be
involved in membrane protein sorting and traﬃcking. MAR-
VEL, a common feature of Physins, Gyrins, Occludin, MAL
and CKLFSF families, is a membrane-associating domain. It
may be part of the machinery of membrane apposition events
[4], such as transport vesicle biogenesis, neurotransmitter
secretion and polarized membrane traﬃcking. Moreover, some
complex diseases such as Bardet–Biedl syndrome, schizophre-
nia and meningococcal diseases have been related to the MAR-
VEL domain [5]. In the cytosotic loop domain of CKLFSF8,
there are two internalization consensus sequences YXXø
(where Ø is a bulky hydrophobic residue). The tyrosine-based
YXXø motif can bind directly to the adaptor protein 2 (AP2)
l2-subunit [6]. AP2 associates with clathrin and is involved in
budding from the plasma membrane.
The epidermal growth factor receptor (EGFR) represents
the classic model system to study mechanisms of receptor
endocytosis and downregulation in mammalian cells [7,8].
EGFRs are rapidly internalized via clathrin-coated pits and
targeted for degradation in lysosomes [9,10]. A number of
molecules regulate EGFR traﬃcking by accelerating ligand-
induced clearance of EGFR from the cell surface [11] or pro-
moting ligand-induced degradation of EGFR [12,13]. Our
study suggests that CKLFSF8 may be an attenuator of
EGF-induced signaling via facilitating ligand-induced receptor
endocytosis and subsequent desensitization.2. Materials and methods
2.1. Cells and reagents
HEK293, HeLa and PC3 cells were maintained in Dulbeccos mod-
iﬁed Eagles medium (DMEM, Life Technologies, USA) containing
10% FBS (Hyclone, USA) and supplemented with penicillinblished by Elsevier B.V. All rights reserved.
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polyclonal antibody against EGFR was obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). The polyclonal antibodies
against pERK1/2 and ERK1/2 were obtained from KANGCHEN
BIO-TECH (Shanghai, China). The monoclonal antibody against b-
actin was obtained from Sigma (St. Louis, MO). The monoclonal anti-
body against EGFR was obtained from Cell Signaling Technology
(Beverly, MA). Human EGF was purchased from PeproTech EC
(London, England). Alexa Fluor 780-labeled IgG secondary antibody
was obtained from Odyssey (Odyssey, Lincoln, NE). Rhodamin- and
FITC-conjugated goat anti-mouse immunoglobulin, monoclonal anti-
bodies against c-myc (9E10), mouse IgG (mIgG) control, and DAPI
were obtained from Sigma (St. Louis, MO).
2.2. Constructs and transient transfection
Human CKLFSF8 cDNA was subcloned into pEGFP-N1 (Clon-
tech, USA) and pcDNA3.1-Myc-His (B) (pCDB for short) vectors
(Invitrogen, USA) with a C-terminal myc tag, conﬁrmed by DNA
sequencing and designated as pEGFP-CKLFSF8 and pCDB-
CKLFSF8. All plasmids were transiently transfected into cells using
electroporation.
2.3. CKLFSF8 siRNA synthesis and electroporation transfection
Double-stranded siRNAs were designed, chemically synthesized and
PAGE puriﬁed free of RNase contamination according to manufac-
turers instructions (Genechem Corporation, Shanghai, China; Table
1). The non-silencing siRNA was conﬁrmed to have no matches with
the complete human genome by a BLAST search in NCBI
(www.ncbi.nlm.nih.gov). All siRNAs were dissolved to a concentration
of 20 lM with buﬀer containing 20 mM KCl, 6 mM HEPES (pH 7.5)
and 0.2 mMMgCl2. Cell density was adjusted to 1 · 106/350 ll and the
indicated amount of siRNA alone or combined with plasmid were
added into the electroporation cup. After standing at room tempera-
ture for 10 min following a single electric pulse (20 ms, 120 V), cells
were plated into culture dishes and grown in the corresponding com-
plete cell culture medium for the indicated time.
2.4. RT-PCR analysis
Cells were collected at indicated time points and RNA was prepared
using TRIzol reagent (Invitrogen Life Technologies) according to the
manufacturers protocol. Reverse transcription (RT) was performed
with the ThermoSCRIPT RT-PCR System (Invitrogen Life Technol-
ogies), according to the manufacturers protocol. A total RNA of 1 lg
was used for the ﬁrst strand cDNA synthesis using oligo (dT) 15 pri-
mer. PCR products were separated via 1.0% agarose gel electrophore-
sis and visualized by ethidium bromide staining.
2.5. Fluorescence microscopy
To determine the transfection eﬃciency and the inhibitory eﬀect of
siRNAs against CKLFSF8, cells transfected with both the pEGFP-
CKLFSF8 plasmid and non-silencing siRNA or siCKLFSF8 were pla-
ted into 24-well plates. Ten hours later, growth medium was changed
to ensure good cell survival. Cells expressing pEGFP-CKLFSF8
fusion protein were observed using ﬂuorescence microscopy (Olympus,
Japan) 24 h after transfection and images were captured by CCD cam-
era (Apogee Instruments Inc., Logan, UT).
2.6. Cell proliferation assay
Twenty-four hours following transfection, cells were trypsinized and
2 · 103 cells/well were seeded into 96-well plates in triplicate with
20 ng/ml EGF in culture medium. Cellular proliferation was deter-
mined once per day. Brieﬂy, for the MTT assay, 10 ll MTT (5 lg/ll
in PBS) was added to each well and cells were incubated at 37 C inTable 1
Sense sequences of the indicated siRNAs
siRNA Targeting sequence
SiCKLFSF8 50-CCGTCTTCTTCCTCATTAT-3 0
GFP siRNA 50-GCAAGCUGACCCUGAAGUUC-30
Non-silencing siRNA 50-UUCUCCGAACGUGUCACGU-3 0a humidiﬁed atmosphere containing 5% CO2. Four to 6 h later, cells
were lysed using cell lysis reagent (20% SDS, 50% DMSO, pH 4.7)
and absorbency was measured at 570 nm with an EL-311SX ELISA
Reader (Bio-Tek Instruments). For the 3H-TdR incorporation assay,
3H-thymidine (3H-TdR) was added (1 lCi/ml) at the indicated time
points. Samples were incubated for 6 h and cells were harvested by a
TOMTEC Harvester 96R onto a 96-well Filtermat (Perkin–Elmer,
Torrance, CA, USA). The incorporation of 3H-TdR was determined
with the MicroBeta Windows Workstation software (Perkin–Elmer).
This experiment was replicated two times.
2.7. Clonogenic assay
After incubation for 48 h at 37 C, transfected cells were trypsinized
and seeded into 100-mm dishes (1000 cells/dish) for HEK293 cells and
6-well plates (350 cells/well) for PC3 and HeLa cells with 20 ng/ml
EGF added. Selection medium with G418 (600–800 mg/ml) was added.
Three weeks later, colonies were ﬁxed and stained with crystal violet
and clones containing more than 50 cells were counted. Each group
was assayed in triplicate dishes, and each experiment was repeated
twice.
2.8. EGF stimulation, cell lysates and immunoassay
Twenty-four hours after incubation at 37 C, transfected cells were
serum-deprived for 20 h and stimulated with 10 ng/ml EGF for the
indicated times. Treated cells were washed with phosphate-buﬀered
saline (PBS) and incubated for 30 min at 4 C in lysis buﬀer (50 mM
Tris–HCL, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium
deoxycholate, 1 mM EDTA, 2 mM Na3VO4, 1 mM NaF and protease
inhibitor cocktail tablets). Cells were harvested and cell lysates were
centrifuged at 18000 · g for 20 min at 4 C. Total protein concentra-
tion of the supernatant was measured using a BCA protein assay kit
(Pierce, USA) with bovine serum albumin as the standard. Thirty
micrograms of total protein was separated on 8% SDS–PAGE and
transferred to nitrocellulose membranes (HybondTM, ECLTM,
Amersham Pharmacia, UK). After blocking in Tris-buﬀered saline
containing 0.05% Tween-20 (TBS-T) and 5% BSA for 1 h at room
temperature, membranes were incubated with corresponding primary
antibodies and Alexa Fluor 780-labeled IgG secondary antibody.
The IR-ﬂuorophores on the membrane were excited at 780 nm and
the emission at 820 nm was quantiﬁed using channel 800 of the LI-
COR Infrared Imaging System (Odyssey, Lincoln, NE) and analyzed
with Odyssey software.2.9. Co-immunoprecipitation
The transfected HEK293 and HeLa cells were lysed at a concentra-
tion of 2 · 107/ml in lysis buﬀer (1% CHAPS, 10 mM Tris/HCL pH
7.4, 150 mM NaCl, 0.02% NaN3, protease inhibitors, 1 mM CaCl2,
and 1 mMMgCl2). After incubation for 30 min on ice, cell lysates were
centrifuged at 18000 · g for 20 min at 4 C to remove insoluble mate-
rial. Cell lysates were pre-cleared for 2 h by addition 1/40 volume pro-
tein G-Sepharose beads (Santa Cruz). After centrifuging at 12000 · g
for 1 min at 4 C, speciﬁc antibodies (3–5 lg) and 20 ll protein G-Se-
pharose beads were added to the supernatants and incubated at 4 C
overnight under constant agitation. Immune complexes were collected
by centrifugation and washed ﬁve times in lysis buﬀer. After the ﬁfth
wash, supernatants were discarded and 10 ll of 2· reducing sample
buﬀer were added into Protein G-Sepharose. The samples were boiled
for 5 min and then analyzed by SDS–PAGE. In the experiment, the
monoclonal antibodies against EGFR were used to co-immunoprecip-
itate pCDB-CKLFSF8 from HEK293 and HeLa cells. The polyclonal
antibodies against EGFR were used to detect EGFR in the pCDB-
CKLFSF8 immunoprecipitates.
2.10. Labeling of transfected cells with anti-EGFR antibody and DAPI
HEK293 and HeLa cells were transfected with pEGFP-CKLFSF8.
1 · 103 cells/well were seeded into MatTek Cultureware (MatTek Cor-
poration, USA). After a 4 h incubation at 37 C, 1 ml fresh medium
was supplemented. At 24 h post-transfection, cells were serum-de-
prived for 20 h and stimulated with 10 ng/ml EGF for the indicated
times. Cells were washed with PBS, ﬁxed and permeabilized in 3%
paraformaldehyde containing 0.1% tritonX-100 for 30 min at 4 C.
Cells were then blocked and incubated with a mouse anti-EGFR
monoclonal antibody and a Rhodamine-conjugated goat anti-mouse
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75% glycerol in PBS or stained with DAPI for 10 min before being im-
aged using a TCS-SP laser-scanning confocal microscope with a 63· oil
immersion lense (Leica Microsystems, Mannheim, Germany).2.11. Analysis of surface EGFR by ﬂow cytometry
The construct and siRNA transfected HEK293 and HeLa cells were
seeded into 12-well plates. Twenty-four hours after transfection, cells
were serum-deprived for 20 h and stimulated with 20 ng/ml EGF for
the indicated times. Treated cells were trypsinized and centrifuged at
1500 rpm for 5 min. Cells were washed with PBS, ﬁxed in 3% parafor-
maldehyde for 30 min at 4 C and then blocked and incubated with a
mouse anti-EGFR monoclonal antibody and a FITC-conjugated goat
anti-mouse immunoglobulin. Cells (3 · 104) were counted by ﬂow
cytometry (FACSCalibur) with an excitation of 488 nm and analyzed
with CELLQuest software (BD Bioscience, USA). This experiment
was replicated three times.2.12. Fractionation and biotin labeling of membrane proteins
After a 24 h incubation at 37 C, cells transfected with the constructs
and siRNAs were serum-deprived for 20 h and treated with 100 ng/ml
EGF for the indicated times. Treated cells were trypsinized and centri-
fuged at 1500 rpm for 5 min. Cells were washed with ice-cold PBS (pH
8.0) to remove amine-containing culture media and proteins from the
cells and suspended at a concentration of 25 · 106 cells/ml in PBS (pH
8.0). Cells were incubated in 200 ll of 10 mM Sulfo-NHS-Biotin
(PIERCE) solution per ml of cell suspension at room temperature
for 30 min. After washing three times with PBS (pH 8.0), 100 mM gly-
cine was added to quench and remove excess biotin reagent and
byproducts. Cells were lysed in SDS lysis buﬀer (1% SDS, 150 mM
NaCl and 50 mM Tris–HCl, and pH 7.4). Soluble proteins were col-
lected after centrifugation at 16000 · g for 10 min and then incubated
overnight at 4 C with 0.2 g of avidin-agarose beads (Calbiochem).
Avidin-agarose beads were pre-treated by incubation with SDS lysis
buﬀer. The beads were washed ﬁnve times in SDS lysis buﬀer to
remove unbound, non-biotinylated proteins and boiled in 2· protein
gel sample buﬀer for 5 min to solubilize biotinylated, bound membrane
proteins prior to analysis by SDS–PAGE and Western blotting with a
polyclonal antibody against EGFR.3. Results
3.1. Transfection of siRNA inhibits CKLFSF8 expression at the
mRNA level
Non-silencing siRNA or siCKLFSF8 were transfected into
HEK293, PC3 and HeLa cell lines either alone or combined
with a plasmid encoding pEGFP-CKLFSF8. CKLFSF8
mRNA levels were signiﬁcantly reduced in cells that were
transfected with siCKLFSF8 24 and 48 h after transfection,
as assessed by RT-PCR (Fig. 1A). Similarly, 24 h after trans-
fection, relative ﬂuorescence intensity in the cells transfected
with siCKLFSF8 were strongly reduced, as assessed by ﬂuo-
rescence microscopy (Fig. 1B) and ﬂow cytometry (Fig. 1C).
In contrast, non-silencing siRNA had no such eﬀects. These
results indicate that siCKLFSF8 robustly and speciﬁcally
inhibits CKLFSF8 expression in HEK293, PC3 and HeLa cell
lines. Therefore, siCKLFSF8 was selected for use in the fol-
lowing experiments.
3.2. Eﬀects of CKLFSF8 and siCKLFSF8 on cell proliferation
HEK293, PC3 or HeLa cells were transiently transfected
with the constructs pCDB, pCDB-CKLFSF8, non-silencing
siRNA or siCKLFSF8 and MTT and 3H-TdR incorporation
assays for measuring cell proliferation were performed. During
a three to ﬁve-day period, cells transfected with pCDB-
CKLFSF8 proliferated slowly compared with pCDB-transfec-
ted cells. In contrast, cells transfected with siCKLFSF8showed an increase in cell proliferation compared with that
of non-silencing siRNA transfected cells (Fig. 2A and B).
Growth curves obtained from pCDB-transfected cells were
similar to those of non-silencing siRNA transfected cells.
Our data suggest that transient inhibition of CKLFSF8
expression promotes cell proliferation, whereas CKLFSF8
overexpression inhibits cell proliferation, suggesting that the
CKLFSF8 protein may play a negative role in cell growth.
To determine the negative role of CKLFSF8 in cell prolifer-
ation over an extended period of growth, clonogenic survival
assays were performed on HEK293, PC3 and HeLa cells trans-
fected with pCDB and pCDB-CKLFSF8. As shown in
Fig. 2C, a signiﬁcant decrease in the number of surviving
colonies was observed in the pCDB-CKLFSF8-transfected
cells compared with pCDB-transfected cells. These results
further verify that CKLFSF8 is a negative regulator for cell
proliferation.3.3. Eﬀects of CKLFSF8 and siCKLFSF8 on EGF-induced
signaling
HEK293 cells were transfected with pCDB, pCDB-
CKLFSF8, non-silencing siRNA or siCKLFSF8. Time-course
analysis of EGFR revealed that overexpression or suppression
of CKLFSF8 expression had little eﬀect on the total levels
of EGFR following EGF stimulation. Analysis of
phosphorylation of ERK1/2, an important molecule in the
EGFR-mediated signaling pathway which is involved in cell
proliferation, showed that after the initial robust phosphoryla-
tion, phosphorylation in pCDB-CKLFSF8 transfected cells
decreased rapidly at the later time points, compared with
changes in the phosphorylation level of ERK1/2 in pCDB
transfected cells (Fig. 3). However, suppressed CKLFSF8
expression by siRNA delayed the decrease of phosphorylation
of ERK1/2. Taken together, the results show that ectopic
expression of CKLFSF8 in cells has a negative eﬀect on
EGF-induced signaling.3.4. CKLFSF8 may be associated with the EGFR membrane
complex
HEK293 and HeLa cells were transfected with pCDB and
pCDB-CKLFSF8. Twenty-four hours after transfection, we
found that the anti-c-myc monoclonal antibody 9E10 co-immu-
noprecipitatedwithEGFR fromHEK293 andHeLa cells. In the
reciprocal experiment using HEK293 and HeLa cells, we
detected pCDB-CKLFSF8 in the EGFR immunoprecipitate
(Fig. 4A). To investigate whether EGF treatment aﬀects the
interaction between CKLFSF8 and EGFR, co-immunoprecipi-
tation experiments were performed after serum-deprived cells
transfected with pCDB and pCDB-CKLFSF8 were stimulated
with 20 ng/ml EGF. The results showed that pCDB-CKLFSF8
and EGFR co-immunoprecipitated with each other even after
EGF treatment (data not shown). Furthermore, in pEGFP-
CKLFSF8 transfected HEK293 and HeLa cells, we used indi-
rect immunoﬂuorescence to observe the localization of EGFR.
Before EGF treatment, pEGFP-CKLFSF8 and EGFR were
localized on the plasma membrane (Fig. 4B, a–c and g–i). Fol-
lowing EGF stimulation for 3 min, most of the pEGFP-
CKLFSF8 and EGFR were internalized into cells and showed
signiﬁcant co-localization (Fig. 4B, d–f and j–l). The above
results suggest that CKLFSF8 may be constitutively associated
with the EGFR membrane complex.
Fig. 1. Transfection of siCKLFSF8 inhibits CKLFSF8 expression at the mRNA level. (A) RT-PCR results for CKLFSF8 mRNA expression.
HEK293, PC3 and HeLa cells were transfected with non-silencing siRNA or siCKLFSF8. At 24 and 48 h post transfection, total RNAs from each
cell group were extracted and RT-PCR experiments were performed. (B) Eﬀects of siRNAs against CKLFSF8 on the expression of pEGFP-
CKLFSF8 fusion protein. HEK293 and HeLa cells were transfected with pEGFP-CKLFSF8 plasmid alone (a and e), co-transfected with
siCKLFSF8 (d and h) or non-silencing siRNA (b and f). Plasmid pEGFP-CKLFSF8 and siRNA against GFP were co-transfected into HEK293 and
HeLa cells (c and g) as a positive control. At 24 h post transfection, cells were observed under ﬂuorescence microscopy. (C) Flow cytometry analysis
of the eﬀects of siRNAs against pEGFP-CKLFSF8. HEK293 and HeLa cells were transfected with pEGFP-CKLFSF8 alone or combined with non-
silencing siRNA, siCKLFSF8 or siRNA against GFP. Twenty-four hours after transfection, relative ﬂuorescence intensity was measured by ﬂow
cytometry. Data are presented as the average (means ± S.D.) of triplicate determinations.
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internalization
Surface EGFR on HEK293 and HeLa cells was analyzed by
ﬂow cytometry. As shown in Fig. 5A, a and g, cells transfected
with pCDB-CKLFSF8 (pink) contained less surface EGFR at
steady state than control cells (green). Following EGF treat-
ment for 5 min, surface EGFR on pCDB-CKLFSF8-transfec-
ted cells decreased signiﬁcantly (Fig. 5A, c and i), compared
with pCDB-transfected cells (Fig. 5A, b and h). On the con-
trary, as shown in Fig. 5A, d and j, cells transfected with siCK-
LFSF8 (purple) contained more surface EGFR at steady state
than non-silencing siRNA-transfected cells (blue). Following
EGF treatment for 5 min, surface EGFR on the siCKLFSF8-
and non-silencing siRNA-transfected cells showed little change
(Fig. 5A, f and l; e and k). The results suggest that CKLFSF8
overexpression may accelerate internalization of EGFR,
whereas CKLFSF8 suppression by siRNA may delay EGFR
internalization.
To further characterize the kinetics of ligand-dependent
removal of EGFR from the cell surface, HeLa cells were trea-
ted with a saturated concentration of EGF for the indicated
times. The amount of receptor remaining on the surface wasassessed by immunoprecipitation after cells were biotinylated.
As shown in Fig. 5B, overexpression of CKLFSF8 in HeLa
cells accelerated ligand-induced clearance of EGFR from the
cell surface, compared with control cells. In contrast, biotinyl-
ated EGFR disappeared from the surface of HeLa cells trans-
fected with siRNA against CKLFSF8, at a relative slow rate
compared with cells transfected with non-silencing siRNA.
To investigate whether enhanced internalization leads to en-
hanced degradation, we labeled cell surface receptors by bio-
tinylation just before EGF treatment and followed their
degradation to see if transfection with CKLFSF8 aﬀects the
degradation rate of surface EGFR. As shown in Fig. 5C,
CKLFSF8 overexpression did not promote speciﬁc degrada-
tion of internalized EGFR compared with control cells. These
results provide further evidence that variation of CKLFSF8
has little eﬀect on the total levels of EGFR.4. Discussion
Epidermal growth factor receptor (EGFR) signaling can be
regulated by various proteins at various levels. CD82, a classi-
Fig. 2. Suppressed CKLFSF8 expression promotes cell proliferation. HEK293, PC3 or HeLa cells were transiently transfected with pCDB, pCDB-
CKLFSF8, non-silencing siRNA or siCKLFSF8. Cell proliferation was determined by MTT (A) and 3H-thymidine incorporation (B) assays. (C)
Clonogenic survival assays were performed to determine the negative role of CKLFSF8 in cell proliferation over an extended period of growth. Data
are presented from one of three separate experiments.
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YXXø in its cytosotic loop domain, is associated with EGFR
and regulates EGFR internalization in several diﬀerent types
of epithelial cells [14]. A predicted MARVEL domain and
two YXXø motifs in the cytosotic loop domain of CKLFSF8
drove us to study the function of CKLFSF8 in the endocytosis
of EGFR. Following EGF treatment, overexpression of
CKLFSF8 inhibited cell proliferation, whereas knockdown
of CKLFSF8 by siRNA promoted cell proliferation. EGF-in-
duced activation of its receptor resulted in phosphorylation of
a number of cellular proteins. ERK1/2 is an important signal-
ing molecule in the EGFR signaling pathway that is involved
in cell proliferation. Therefore, in the present study, we
hypothesized that CKLFSF8 may had a negative eﬀect on
EGFR signaling.
After the initial robust phosphorylation of ERK1/2, phos-
phorylation decreased rapidly in CKLFSF8-overexpressing
cells following EGF treatment, whereas phosphorylation of
ERK1/2 in siCKLFSF8 transfected cells showed a slowdecrease. Members of proteins with a MARVEL domain have
been demonstrated to be essential components of membrane
traﬃcking in epithelial and endothelial cells [15,16]. However,
to our knowledge, none of the proteins have been reported to
regulate EGFR signaling. CKLFSF8 is associated with the
EGFR membrane complex, thus providing the ﬁrst example
of a MARVEL-containing protein that regulates EGFR
signaling.
Internalization and intracellular traﬃcking of the stimulated
EGFRs are important for diversifying intracellular signals [17].
Dissociation of the endocytosed EGF-EGFR complex in late
endosomes and lysosomes leads to desensitization of the recep-
tor and attenuation of EGF-induced signaling. Thus, in the
present study, we hypothesized that variation of CKLFSF8
levels in cells may aﬀect ligand-induced degradation of EGFR.
Our experiments demonstrated that CKLFSF8 overexpression
or suppression has little eﬀect on the total levels of EGFRs and
CKLFSF8 overexpression does not accelerate degradation
of internalized EGFR. These results suggest that the negative
Fig. 3. Eﬀects of CKLFSF8 and siCKLFSF8 on EGF-induced signaling. HEK293 and HeLa cells were transfected with pCDB, pCDB-CKLFSF8,
non-silencing siRNA or siCKLFSF8. Twenty-four hours after transfection, cells were stimulated with EGF and stained for EGFR, pERK1/2,
ERK1/2 and beta-actin. Experiments were performed in triplicate, all with similar results.
Fig. 4. CKLFSF8 may be associated with the EGFR membrane complex. (A) The anti-c-myc monoclonal antibody 9E10 co-immunoprecipitates
with EGFR from HEK293 and HeLa cells. In the reciprocal experiment, pCDB-CKLFSF8 was detected in the EGFR immunoprecipitates using the
anti-c-myc monoclonal antibody 9E10. Isotype-matched mouse monoclonal antibody IgG (mIgG) was used as a control. (B) HEK293 and HeLa cells
were transfected with pEGFP-CKLFSF8. Twenty-four hours after transfection, cells were serum-deprived for 20 h and stimulated with EGF. Before
and after EGF treatment, we used indirect immunoﬂuorescence to observe the localization of EGFR and pEGFP-CKLFSF8. Before EGF treatment,
pEGFP-CKLFSF8 (a and g, green) and EGFR (b and h, red) were localized on the plasma membrane. Images are overlaid in c and i. Following
EGF stimulation, most of the pEGFP-CKLFSF8 (d and j, green) and EGFR (e and k, red) were internalized into cells. Images are overlaid in f and l.
Experiments were performed in triplicate, with similar results.
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caused by promoting speciﬁc degradation of EGFR. To
investigate whether rapid downregulation of signaling in
CKLFSF8-overexpressing cells correlates with an increase in
the EGFR internalization rate, we examined the removal of
EGFR from the cell surface after cells were treated with thevarying concentrations of EGF. The results from our experi-
ments showed that overexpression of CKLFSF8 in HeLa
and HEK293 cells accelerated ligand-induced clearance of
EGFR from the cell surface, whereas CKLFSF8 suppression
by siRNA had the opposite eﬀect on EGFR internalization.
The majority of the internalized receptors are destined for
Fig. 5. Eﬀects of CKLFSF8 and siCKLFSF8 on EGFR internalization. (A) Flow cytometry analysis of surface EGFR. The pCDB, pCDB-
CKLFSF8, non-silencing siRNA or siCKLFSF8 transfected HEK293 and HeLa cells were treated as described in Section 2. Surface EGFR on
HEK293 and HeLa cells were analyzed by ﬂow cytometry. Cells transfected with pCDB-CKLFSF8 (pink) contained less surface EGFR at steady
state than control cells (a and g, green). Following EGF treatment, surface EGFR on pCDB-CKLFSF8 transfected cells decreased signiﬁcantly (c
and i) compared with pCDB transfected cells (b and h). In contrast, cells transfected with siCKLFSF8 (purple) contained more surface EGFR at
steady state than non-silencing siRNA transfected cells (d and j, blue). Following EGF treatment, surface EGFR on siCKLFSF8 and non-silencing
siRNA transfected cells showed little change (f and l; e and k). (B) Kinetics of ligand-dependent removal of EGFR from the cell surface. HeLa cells
transfected with pCDB, pCDB-CKLFSF8, non-silencing siRNA or siCKLFSF8 were treated with EGF for the indicated times. The amount of
receptor remaining on the cell surface was assessed by immunoprecipitation after cells were biotinylated. (C) Enhanced internalization did not lead to
enhanced degradation. HeLa cells transfected with pCDB and pCDB-CKLFSF8 were biotinylated before EGF stimulation for the indicated times.
The amount of biotinylated EGFR was assessed by immunoprecipitation. Experiments were performed in duplicate, with similar results.
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Although there are reports that the internalized EGF–EGFR
complex maintains its ability to generate cell signaling from
endosomes [18–20], the biological signiﬁcance of compart-
ment-restricted signaling in the context of the EGFR system
is unclear. At present, it is widely accepted that removal of
EGFR from the cell surface by directing them to the endocytic
pathway is expected to inhibit their oncogenic potential. Thus,
the enhanced rate of endocytosis can account for the rapid
attenuation of EGF-induced signaling in the cells transfected
with CKLFSF8.
The EGF family of polypeptides is crucial to various normal
and pathological processes, including tissue diﬀerentiation,
wound healing and tumorigenesis. EGF-induced signaling is
controlled at various levels, including ligand-induced dimeriza-
tion of EGFR [21], membrane compartmentalization of the
activated routing of the receptor and its ligands [22] and intra-
cellular routing of the receptor and its degradation [23].
Although the molecular mechanisms underlying these pro-
cesses are not fully understood, they are each thought to in-
volve distinct interactions between EGFR and other cellular
proteins. Our results identify CKLFSF8 as a novel attenuator
of EGF-induced signaling, accelerating clearance of ligand-
bound EGFR from the cell surface. These data provide further
support for the idea that ligand-induced endocytosis of surface
receptors is an integral part of the signaling process that con-
trols the amplitude of cellular responses [24]. EGFR and
CKLFSF8 are expressed together in a variety of normal tissues
[2]. Our results suggest that a change in the relative expression
of these proteins in tumors (for example, downregulation of
CKLFSF8 or overexpression of EGFR) would aﬀect an
important suppressive control on EGF-induced signaling.
The consequent sustained activation of EGFR and protracted
generation of proliferation signals could enable the progres-
sion of the disease.
In conclusion, we have identiﬁed CKLFSF8 as a novel
negative regulator of EGF-induced signaling via facilitation
of ligand-induced receptor endocytosis and subsequent desen-
sitization. These results may be of value in elucidating the
mechanisms underlying EGFR endocytosis and signaling.
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